Case File
efta-01879144DOJ Data Set 10OtherEFTA01879144
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01879144
Pages
3
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
Julien Boillot
Cc:
kareml
From:
Jeffrey Epstein
Sent:
Tue 6/26/2012 11:40:04 AM
Subject: Re: Spacs
not exactly , but there arc many pros and cons.. we buy an already existing spac„ many arc for
sale the we arc selling interests in the spc.. theree is no ipo involved.
On Tuc, Jun 26, 2012 at 11:45 AM, Julien Boillot
wrote:
I had a close look at the various data on SPACs and I am not entirely certain it will
work for us at least at the holding level. I am certainly not ruling out the concept
(which is very clever) and I outline below the issues that I have (based on my
understanding) for discussions purposes.
SPACs are by definition a pot of cash raised via an IPO in order to make the
acquisition of an existing business and fund, when necessary, its development. This
raises two questions: (i) can we use a SPAC to make acquisition of several
companies in various sectors and (ii) can we use a SPAC to start a business from
scratch.
From the information I gathered, SPACs are flexible structures and could therefore
be setup to answer the above questions but I have the feeling that by doing so, we
may go away from the main objective of SPACs: a visible quoted vehicle attracting
liquidity and fair valuation. In our case, our investment company intends to make
acquisitions and invest in greenfield projects in various sectors in Africa, two
reasons to apply a discount to the holding company. I do not know whether my
reasoning is correct and this is certainly a good topic for discussions.
Going forward, I believe that we could create a type of company that answers almost
all our requirements:
Ensuring a traded value for the investments made seems to be
difficult at least in the first 2 years. For business acquired, we could
introduced SPACs as "affiliates" of the Investment company. Investco
would try to retain control of the business.
EFTA_R1_00290553
EFTA01879144
-
Exit flexibility. This is a difficult one in both a limited company and
limited liability partnership (maybe more difficult in this latter case). I am
not sure how this can be covered other than on abest effort basis.
-
Interest of management aligned on that of investors. This can be
done by either giving shares to the management in a limited company or
by granting the management a share of profits in a limited liability
partnership.
-
Avoid unexpected dilutions of initial investors. A similar concept of
warrants can be put in place in the case of a limited company. This is more
difficult in a partnership as it will require a heavier legal documentation. In
this case, one has to think from the outsetwhat terms and conditions will
be offered to initial investors in the event of a second (or more) rounds of
contribution.
-
Other requirements ...
At this stage, I think we may have to stick to the original concept of an investment
company be it a Limited Liability Company or a Limited Liability Partnership. We are
assessing the pros and cons of both options and will revert soon.
Best regards,
J
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
EFTA_R1_00290554
EFTA01879145
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation@gmail com and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA_R1_00290555
EFTA01879146
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.